NCT05377047 Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
| NCT ID | NCT05377047 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vastra Gotaland Region |
| Condition | Breast Cancer Stage IV |
| Study Type | INTERVENTIONAL |
| Enrollment | 345 participants |
| Start Date | 2022-09-19 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 345 participants in total. It began in 2022-09-19 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.
Eligibility Criteria
Inclusion Criteria: 1. Histologically or cytological confirmed recurrent OMBC. 2. Age ≥18 years old. 3. OMBC defined as 1-5 metastases in a maximum of two organs confirmed by PET-CT. 4. Patients already on 1st line systemic treatment can be enrolled if repeated tumour evaluations show stable disease. 5. Patients with de novo stage IV OMBC must have a controlled primary tumour regardless of primary surgery or primary systemic treatment. 6. Patients with local recurrence and OMBC must have a controlled local recurrence. 7. ECOG/WHO 0-2. 8. Life expectancy \> 6 months. 9. Known ER, PgR and HER2 status of either primary tumour or metastasis (preferred). 10. If measurable lesions, each ≤ 5 cm. 11. Symptomatic bone metastases are allowed if ablative therapy can be delivered (femoral metastasis not allowed). 12. Adequate organ function for the planned treatment according to local guide-lines. 13. For patients with liver metastasis: * No cirrhosis or hepatitis * Hepatic function: * Total bilirubin level \< 3.0 x institutional ULN * ALT, AST, GGT, and alkaline phosphatase levels \< 3.0 x institutional ULN * Albumin \> 2.5 mg/dL * Metastasis not adjutant to stomach or small bowel. 14. For patients with abdominal metastases: adequate renal function with a calculated creatinine clearance of \> 60mL/min. 15. Toxicities from previous adjuvant therapies (excluding alopecia) must have recovered to grade 1 (defined by CTCAE 5.0). Stable grade 2 peripheral neuropathy are considered individually by the investigator. 16. Negative pregnancy test within 14 days prior to start of treatment\*. 17. If childbearing potential, willing to use an effective form of contraception\*. 18. No other malignancy during the last 5 years except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix. 19. Signed informed consent and willingness to follow the trial procedures. Exclusion Criteria: 1. \> 1 line of systemic treatment for OMBC due to previous progressing disease (previous treatment of isolated local recurrences with a 2nd adjuvant treatment not included). 2. Oligometastases in brain. 3. Malignant pleural effusion or ascites. 4. Metastasis growth that involves \> 3 vertebra and adjacent spinal cord, spine instability or neurological deficit resulting from compression, 25% spinal canal compromise or progressive neurological deficit. 5. Unable to undergo imaging by either CT scan or MRI. 6. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance. 7. Pregnancy or breast-feeding. 8. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).
Contact & Investigator
Barbro K Linderholm, MD, PhD
PRINCIPAL INVESTIGATOR
Sahlgrenska University Hospital, Gothenburg
Frequently Asked Questions
Who can join the NCT05377047 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer Stage IV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05377047 currently recruiting?
Yes, NCT05377047 is actively recruiting participants. Contact the research team at katarzyna.kulbacka-ortiz@vgregion.se for enrollment information.
Where is the NCT05377047 trial being conducted?
This trial is being conducted at Gothenburg, Sweden.
Who is sponsoring the NCT05377047 clinical trial?
NCT05377047 is sponsored by Vastra Gotaland Region. The principal investigator is Barbro K Linderholm, MD, PhD at Sahlgrenska University Hospital, Gothenburg. The trial plans to enroll 345 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.